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Volume 60, Number 5 Abstracts 1395Inpatient Register and the Swedish National Register for Vascular Surgery
(Swedvasc). Associations were estimated with Cox proportional hazards
models. The cohorts included 35,550 women and 42,596 men, aged 46
to 84 years. During follow-up, AAA was identiﬁed in 199 women and
958 men. The incidence of AAA per 100,000 person-years was 76 among
men who never smoked and 136 among women who currently smoked.
Regarding AAA risk, women were more sensitive to current smoking
(P interaction ¼ .002). Compared with never smokers, the hazard ratio
(HR) for AAA in current smokers with more than 20 pack-years was
10.97 (95% conﬁdence interval [CI], 7.41-16.26) among women and
6.55 (95% CI, 5.36-7.99) among men. Following smoking cessation,
women had a more rapid decline in excess risk (P interaction < 0.001). The
risk was halved after 11 years (HR, 0.51; 95% CI, 0.32-0.81) among
women and after 23 years (HR, 0.50; 95% CI, 0.42-0.60) among men.
Comment: The data suggests that although women are not generally
included in AAA screening programs, women who smoke have a higher
incidence of AAA than men who never smoked. It also appears that women
are more sensitive to current tobacco exposure with regard to AAA risk and
that smoking cessation decreasing the risk of AAA twice as quickly among
women than men. It therefore appears that targeted screening for AAA in
women should be investigated further with both screening based studies
and cost-effectiveness analyses.
Vein Graft Preservation Solutions, Patency, and Outcomes After
Coronary Artery Bypass Graft Surgery: Follow-up From PREVENT
IV Randomized Clinical Trial
Harskamp RE, Alexander JH, Schulte PJ, et al. JAMA Surg 2014;149:
798-805.
Conclusions: Patients undergoing coronary artery bypass grafting
with vein grafts preserved in a buffered saline solution had lower graft failure
rates and trends toward better long-term clinical outcomes compared with
patients whose grafts were preserved in saline or blood-based solutions.
Summary: After harvesting a vein graft for implantation in the coro-
nary or peripheral circulation, the graft may be temporarily stored in a pres-
ervation solution. There’s great variation among hospitals and surgeons as
to the choice of preservation solution. Such solutions range from physio-
logic saline to autologous blood and to solutions that contain ions for pH
buffering, antioxidants, and ionic compositions similar to intracellular ﬂuid.
All solutions have not been compared in clinical trials. In this study the au-
thors performed an observational comparative-effectiveness evaluation of
various vein graft preservation solutions using data from the PREVENT
IV trial. This was a large randomized clinical trial of patients undergoing
CABG surgery. The patterns of vein graft preservation solutions in clinical
practice were delineated and vein graft failure rates at 1-year and long-
term clinical outcomes after CABG surgery among patients whose grafts
were treated with various preservation solutions were compared. PREVENT
IV was the coronary bypass parallel study of PREVENT III. Both were
phase 3, multicenter, randomized, double-blind, placebo-controlled trials,
of treatment of vein grafts with E2F transcription factor decoy edifoligide
in patients undergoing either peripheral vein graft bypass for lower extrem-
ity critical arterial ischemia (PREVENT III) or coronary artery bypass graft-
ing (PREVENT IV). PREVENT IV took place at 107 U.S. sites from
August 1, 2002 through October 22, 2003. To participate in PREVENT
IV, the patient needed to be undergoing CABG surgery with at least 2
planned vein grafts. In this study the vein grafts were stratiﬁed for whether
they were preserved in a saline, blood or buffered saline solution. The main
outcome measure was one-year angiographic vein graft failure and 5-year
rates of death, myocardial infarction, and subsequent revascularization. Sa-
line solution was the most common preservation solution (1339 [44.4%]
patients), followed by blood (971 [32.2%]), and buffered saline (507
[16.8%]). Baseline characteristics were similar among groups. One-year
vein graft failure rates were lower in the buffered saline group than in the
saline group (patient-level odds ratio, 0.59; 95% conﬁdence interval [CI],
0.45-0.78; P < .001; graft-level odds ratio, 0.63; 95% CI, 0.49-0.79;
P < .001) for the blood group (patient level odds ratio, 0.62; 95% CI,
0.46-0.83; P ¼ .001; graft level odds ratio, 0.63; 95% CI, 0.48-0.81;P < .001). Buffered saline solution also tended to be associated with a lower
5-year risk for death, myocardial infarction, or subsequent revascularization
compared with saline (hazard ratio, 0.81; 95% CI, 0.64-1.02; P ¼ .08) and
blood (0.81; 95% CI, 0.63-1.03; P ¼ .09) solutions.
Comment: One has to wonder if the physiologic pH and isotonic
milieu provided by buffered saline contributed to the observed vein reduc-
tion vein graft failure rates, why such a reduction was not seen with blood
based preservative as well. One must recognize the possibility of a number
of unaccounted for confounding variables such as degree of hydrostatic vein
graft distension, traction injury, among others that may have also contrib-
uted to this ﬁnding. In addition, clearly the ﬂow characteristics of the cor-
onary and peripheral circulations are not the same and one wonders
whether the data can truly be extrapolated to peripheral artery bypass sur-
gery. Perhaps a similar analysis with respect to peripheral bypass surgery
will be forthcoming from the PREVENT III investigators?
Statin Use and Rupture of Abdominal Aortic Aneurysm
Wemmelund H, Høgh A, Hundborg HH, et al. Br J Surg 2014;101:
966-75.
Conclusions: Statin use is associated with a reduced risk of rupture of
abdominal aortic aneurysm (AAA) and lower case fatality following rupture
of AAA.
Summary: There have been studies suggesting that statins may
reduce AAA growth rates and rupture risk by enhancing endothelial func-
tion and attenuating oxidative stress and inﬂammation of the vessel wall
(Liao JK. Am J Cardiol 2005;96:24F-33F). Meta-analyses also suggests
decreased growth rate of AAAs with the use of statins (Sweeting MJ et al,
Br J Surg 2012;99:655-65). In addition there have been small, single-center
observational studies suggesting an association between prehospital statin
therapy and lower mortality following surgery for ruptured (rAAA) (Feeney
JM et al, J Am Coll Surg 2009;209:41-6). In the current study the authors
use the Danish National Registry of Patients, to examine incident rAAA
cases and AAA control patients with a focus on the risk and prognosis of
rAAA. This was a nationwide, population-based, combined case-control
and follow-up study that included all patients (aged at least 50 years) with
a ﬁrst-time hospital admission for rAAA and 1:1 matched AAA controls
without rupture in Denmark, from 1996 to 2008. Individual-level data
on preadmission drug use, comorbidities, socioeconomic markers, health-
care contacts and death were obtained from nationwide registries. The study
included 3584 cases and 3584 match controls. Current statin use was regis-
tered for 418 patients with rAAA (11.7%) and 539 AAA controls (15.0%),
corresponding to an age- and sex-matched odds ratio of 0.7 (95% CI, 0.60-
0.81) for rAAA in current statin users vs never users. The decreased risk of
rAAA remained after adjustment for potential confounding factors (adjusted
OR, 0.73; 95% CI, 0.61-0.86). Overall, 30-day mortality rate from time of
hospital admission among patients with rAAA was 46.1% in current statin
users compared with 59.3% in never users (adjusted mortality rate
[MRR], 0.80, 95% CI, 0.68-0.95). Patients who had formerly used statins
did not have reduced mortality (adjusted MRR, 0.98; 95% CI, 0.78-1.22).
Comment: The study suggests beneﬁts for statins in patients with
AAA both in lower rupture rates and improved survival of ruptures. How-
ever, it has a number of signiﬁcant limitations in that there was no data
on AAA diameter, a known predictor of rupture. It may also be possible
that patients who use statins are more cooperative in adherence to medical
recommendations and have greater contact with a healthcare system, and
therefore are overall more healthy and have their aneurysms diagnosed at
a smaller size prior to rupture, where they can be ﬁxed electively. Neverthe-
less, given that patients with AAA generally have manifestations of athero-
sclerosis and vascular disease other than AAA that are considered to
beneﬁt from statins, there seems to be no downside to placing patients
with AAAs on a statin medication. Certainly additional analyses of possible
mechanism of beneﬁt are needed, but for the moment the results of this
study support current guidelines that recommend initiation of prophylactic
statin treatment in asymptomatic patients with AAA (Chaikof EL et al, J
Vasc Surg 2009;50(Suppl):S2-S49, and Moll FL, Eur J Vasc Endovasc
Surg 2011;41(Suppl 1):S1-S58).
